

Paul A Gurbel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5010605/publications.pdf>

Version: 2024-02-01

377
papers

25,507
citations

12303

69
h-index

7333

152
g-index

394
all docs

394
docs citations

394
times ranked

12862
citing authors

#	ARTICLE	IF	CITATIONS
1	Clopidogrel for Coronary Stenting. <i>Circulation</i> , 2003, 107, 2908-2913.	1.6	1,470
2	Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 849.	3.8	1,319
3	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. <i>Journal of the American College of Cardiology</i> , 2010, 56, 919-933.	1.2	1,058
4	Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. <i>Circulation</i> , 2009, 120, 2577-2585.	1.6	1,035
5	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1821.	3.8	980
6	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	1.2	807
7	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	13.9	765
8	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. <i>Lancet</i> , The, 2013, 382, 614-623.	6.3	740
9	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	13.9	683
10	Platelet Reactivity in Patients and Recurrent Events Post-Stenting. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1820-1826.	1.2	628
11	Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1827-1832.	1.2	525
12	Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance. <i>Circulation</i> , 2004, 109, 166-171.	1.6	449
13	Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1852-1856.	1.2	438
14	Platelet Function Monitoring in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1822-1834.	1.2	437
15	Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. <i>Circulation</i> , 2010, 121, 1188-1199.	1.6	419
16	Evaluation of Dose-Related Effects of Aspirin on Platelet Function. <i>Circulation</i> , 2007, 115, 3156-3164.	1.6	379
17	Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2007, 49, 657-666.	1.2	378
18	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	1.1	366

#	ARTICLE	IF	CITATIONS
19	Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets. <i>Circulation</i> , 2005, 111, 1153-1159.	1.6	350
20	The Relation of Dosing to Clopidogrel Responsiveness and the Incidence of High Post-Treatment Platelet Aggregation in Patients Undergoing Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1392-1396.	1.2	345
21	Overestimation of Platelet Aspirin Resistance Detection by Thrombelastograph Platelet Mapping and Validation by Conventional Aggregometry Using Arachidonic Acid Stimulation. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1705-1709.	1.2	306
22	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015, 36, 1762-1771.	1.0	297
23	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
24	The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1199-1204.	1.2	260
25	Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 261-269.	1.4	244
26	The Association of Cigarette Smoking With Enhanced Platelet Inhibition by Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2008, 52, 531-533.	1.2	211
27	The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients. <i>Diabetes</i> , 2007, 56, 3014-3019.	0.3	206
28	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1785.	3.8	200
29	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	6.1	180
30	First Analysis of the Relation Between <i>CYP2C19</i> Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 556-566.	5.1	163
31	Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1017-1023.	1.2	160
32	Effects of Reteplase and Alteplase on Platelet Aggregation and Major Receptor Expression During the First 24 Hours of Acute Myocardial Infarction Treatment. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1466-1473.	1.2	157
33	Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study. <i>Journal of the American College of Cardiology</i> , 2010, 56, 185-193.	1.2	157
34	Clopidogrel resistance?. <i>Thrombosis Research</i> , 2007, 120, 311-321.	0.8	151
35	Optimal Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2013, 158, 261.	2.0	151
36	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021, 121, 422-432.	1.8	149

#	ARTICLE	IF	CITATIONS
37	Adenosine diphosphate-induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events. <i>American Heart Journal</i> , 2010, 160, 346-354.	1.2	145
38	The difference between clopidogrel responsiveness and posttreatment platelet reactivity. <i>Thrombosis Research</i> , 2005, 115, 89-94.	0.8	138
39	First report of the point-of-care TEG: A technical validation study of the TEG-6S system. <i>Platelets</i> , 2016, 27, 642-649.	1.1	133
40	The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 1-8.	0.7	130
41	The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel. <i>Journal of the American College of Cardiology</i> , 2013, 62, 505-512.	1.2	128
42	Durability of platelet inhibition by clopidogrel. <i>American Journal of Cardiology</i> , 2003, 91, 1123-1125.	0.7	121
43	Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. <i>American Heart Journal</i> , 2003, 145, 239-247.	1.2	119
44	Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. <i>American Journal of Cardiology</i> , 1999, 83, 1345-1349.	0.7	118
45	Combination Antithrombotic Therapies. <i>Circulation</i> , 2010, 121, 569-583.	1.6	112
46	Effect of <i>CYP2C19*2</i> and <i>*3</i> Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated With Clopidogrel and Aspirin. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 585-594.	1.4	112
47	Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents. <i>Circulation</i> , 2012, 125, 1276-1287.	1.6	111
48	Drug Insight: clopidogrel nonresponsiveness. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 387-395.	3.3	105
49	Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. <i>Platelets</i> , 2008, 19, 595-604.	1.1	101
50	Genetic Variation in <i>PEAR1</i> Is Associated With Platelet Aggregation and Cardiovascular Outcomes. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 184-192.	5.1	97
51	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	1.0	93
52	Comparative Efficacy and Safety of Oral P2Y ₁₂ Inhibitors in Acute Coronary Syndrome. <i>Circulation</i> , 2020, 142, 150-160.	1.6	93
53	Genotyping. <i>Journal of the American College of Cardiology</i> , 2010, 56, 112-116.	1.2	90
54	Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 189-197.	1.1	89

#	ARTICLE	IF	CITATIONS
55	Advances in Antiplatelet Therapy: Agents in Clinical Development. American Journal of Cardiology, 2009, 103, 40A-51A.	0.7	88
56	The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype: first experience in patients. Journal of Thrombosis and Haemostasis, 2010, 8, 43-53.	1.9	87
57	Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 1500-1509.	1.2	85
58	Effect of Clopidogrel With and Without Eptifibatide on Tumor Necrosis Factor-Alpha and C-Reactive Protein Release After Elective Stenting. Journal of the American College of Cardiology, 2006, 48, 2186-2191.	1.2	84
59	Bleeding and thrombosis associated with ventricular assist device therapy. Journal of Heart and Lung Transplantation, 2017, 36, 1164-1173.	0.3	83
60	Platelet activation in myocardial ischemic syndromes. Expert Review of Cardiovascular Therapy, 2004, 2, 535-545.	0.6	82
61	A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y ₁₂ Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2012, 5, 336-346.	1.4	81
62	Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients. Journal of the American College of Cardiology, 2013, 62, 577-583.	1.2	81
63	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. European Heart Journal, 2021, 42, 4638-4651.	1.0	80
64	The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. American Heart Journal, 2011, 161, 598-604.	1.2	78
65	Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. American Heart Journal, 2000, 139, 320-328.	1.2	77
66	The Effect of St John's Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity. Journal of Cardiovascular Pharmacology, 2011, 57, 86-93.	0.8	77
67	Usefulness of the VerifyNow P2Y ₁₂ assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. American Heart Journal, 2012, 164, 35-42.	1.2	77
68	Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. Nature Biomedical Engineering, 2020, 4, 1188-1196.	11.6	77
69	The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. American Heart Journal, 2011, 162, 160-165.	1.2	75
70	Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: Results of the Thrombotic Risk Progression (TRIP) Study. Platelets, 2010, 21, 360-367.	1.1	73
71	Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 989-1004.	1.5	70
72	Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. American Journal of Cardiology, 2001, 87, 1398-1400.	0.7	69

#	ARTICLE	IF	CITATIONS
73	Aspirin Resistance. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 141-152.	1.6	69
74	Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 648-657.	1.2	68
75	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <i>Circulation</i> , 2019, 139, 2170-2185.	1.6	66
76	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 578-586.	1.2	66
77	Resistance to antiplatelet drugs: current status and future research. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2027-2045.	0.9	65
78	Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001683.	1.4	65
79	Dark Chocolate Effect on Platelet Activity, C-Reactive Protein and Lipid Profile: A Pilot Study. <i>Southern Medical Journal</i> , 2008, 101, 1203-1208.	0.3	64
80	Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases. <i>Stroke</i> , 2014, 45, 492-503.	1.0	63
81	Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 437-445.	1.0	63
82	G-Proteinâ€“Coupled Receptors Signaling Pathways in New Antiplatelet Drug Development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 500-512.	1.1	60
83	The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. <i>American Heart Journal</i> , 2009, 158, 784.e1-784.e6.	1.2	59
84	Platelet-Mediated Thrombosis. <i>Circulation Research</i> , 2016, 118, 1380-1391.	2.0	56
85	Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis. <i>American Journal of Cardiology</i> , 2009, 104, 525-530.	0.7	54
86	Clopidogrel Efficacy and Cigarette Smoking Status. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2495-6.	3.8	54
87	Antiplatelet and Anticoagulant Agents in Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 1-14.	1.9	54
88	Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. <i>American Heart Journal</i> , 1998, 136, 398-405.	1.2	53
89	Clinical Utility of Available Methods for Determining Platelet Function. <i>Cardiology</i> , 1999, 92, 240-247.	0.6	53
90	Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 111-121.	1.1	52

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease. <i>Clinical Pharmacokinetics</i> , 2012, 51, 397-409.	1.6	52
92	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 3132-3140.	1.0	52
93	Aspirin and Clopidogrel Resistance: Consideration and Management. <i>Journal of Interventional Cardiology</i> , 2006, 19, 439-448.	0.5	51
94	Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. <i>Thrombosis Research</i> , 2007, 121, 107-115.	0.8	51
95	Clopidogrel and Proton Pump Inhibitors. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 365-380.	1.1	51
96	AZD6140. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 225-229.	1.9	50
97	Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis. <i>American Heart Journal</i> , 2014, 168, 530-536.	1.2	50
98	Platelet function measured by VerifyNow [®] identifies generalized high platelet reactivity in aspirin treated patients. <i>Platelets</i> , 2007, 18, 414-423.	1.1	48
99	Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. <i>Clinical Cardiology</i> , 2017, 40, 1352-1356.	0.7	48
100	Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. <i>Thrombosis Research</i> , 2007, 119, 563-570.	0.8	46
101	Effect of Long-Term Clopidogrel Treatment on Platelet Function and Inflammation in Patients Undergoing Coronary Arterial Stenting. <i>American Journal of Cardiology</i> , 2009, 103, 1546-1550.	0.7	46
102	Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 268-275.	0.5	44
103	Increased soluble platelet / endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. <i>European Journal of Heart Failure</i> , 1999, 1, 243-249.	2.9	43
104	Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. <i>Platelets</i> , 2004, 15, 95-99.	1.1	43
105	The link between heightened thrombogenicity and inflammation: Pre-procedure characterization of the patient at high risk for recurrent events after stenting. <i>Platelets</i> , 2009, 20, 97-104.	1.1	43
106	The drug-drug interaction between proton pump inhibitors and clopidogrel. <i>Cmaj</i> , 2009, 180, 699-700.	0.9	43
107	Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 221-234.	1.4	43
108	Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research. <i>JACC Basic To Translational Science</i> , 2016, 1, 73-86.	1.9	42

#	ARTICLE	IF	CITATIONS
109	Antiplatelet Drug Resistance and Drug-Drug Interactions: Role of Cytochrome P450 3A4. <i>Pharmaceutical Research</i> , 2006, 23, 2691-2708.	1.7	41
110	Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 95.	1.8	40
111	CLOPIDOGREL: THE FUTURE CHOICE FOR PREVENTING PLATELET ACTIVATION DURING CORONARY STENTING?. <i>Pharmacological Research</i> , 1999, 40, 107-111.	3.1	39
112	Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. <i>Thrombosis and Haemostasis</i> , 2010, 103, 535-544.	1.8	39
113	Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: A potential approach to identify atherosclerotic disease progression. <i>American Heart Journal</i> , 2008, 155, 56-61.	1.2	38
114	Noncanonical Matrix Metalloprotease 1 α Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1368-1380.	1.1	38
115	Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. <i>European Heart Journal</i> , 2012, 33, 2151-2162.	1.0	37
116	Evaluation of platelets in heart failure: Is platelet activity related to etiology, functional class, or clinical outcomes?. <i>American Heart Journal</i> , 2002, 143, 1068-1075.	1.2	36
117	An Initial Experiment With Personalized Antiplatelet Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1136.	3.8	36
118	Hypothesis formulation from subgroup analyses: Nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to aspirin resistance. <i>American Heart Journal</i> , 2010, 159, 744-748.	1.2	35
119	Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy?. <i>Annals of Thoracic Surgery</i> , 2016, 102, 2010-2017.	0.7	35
120	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016, 67, 936-947.	1.2	35
121	Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. <i>American Heart Journal</i> , 2001, 142, 611-616.	1.2	34
122	The role of platelet receptors and adhesion molecules in coronary artery disease. <i>Coronary Artery Disease</i> , 2003, 14, 65-79.	0.3	34
123	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Science Bulletin</i> , 2019, 64, 166-179.	4.3	34
124	Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. <i>American Journal of Cardiology</i> , 2002, 90, 312-315.	0.7	33
125	Inflammatory changes during the "common cold" are associated with platelet activation and increased reactivity of platelets to agonists. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 713-718.	0.5	33
126	The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, 117-120.	0.7	33

#	ARTICLE	IF	CITATIONS
127	Omeprazole. <i>Journal of the American College of Cardiology</i> , 2008, 51, 261-263.	1.2	33
128	Pharmacokinetic and Pharmacodynamic Effects of Elinogrel. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 347-356.	1.4	33
129	Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1594-1596.	1.8	33
130	Time dependence of clopidogrel loading effect: Platelet activation versus platelet aggregation. <i>Thrombosis Research</i> , 2012, 129, 1-2.	0.8	32
131	Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. <i>Thrombosis and Haemostasis</i> , 2013, 109, 808-816.	1.8	32
132	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. <i>Thrombosis and Haemostasis</i> , 2016, 115, 823-825.	1.8	32
133	Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1851-1865.	0.9	32
134	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1067-1077.	2.3	32
135	Antiplatelet therapy: current strategies and future trends. <i>Future Cardiology</i> , 2006, 2, 343-366.	0.5	31
136	Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians?. <i>Current Vascular Pharmacology</i> , 2018, 16, 459-476.	0.8	31
137	Resistance to antiplatelet drugs: what progress has been made?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2553-2564.	0.9	30
138	Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity. <i>American Journal of Cardiology</i> , 2015, 115, 716-723.	0.7	30
139	Effect of Thrombolytic Therapy on Platelet Expression and Plasma Concentration of PECAM-1 (CD31) in Patients With Acute Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 153-158.	1.1	29
140	Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: The Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. <i>American Heart Journal</i> , 2003, 145, 636-642.	1.2	29
141	Clopidogrel response variability and the advent of personalised antiplatelet therapy. <i>Thrombosis and Haemostasis</i> , 2011, 106, 265-271.	1.8	29
142	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1607-1617.	1.1	29
143	Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Duration, Resistance, Alternatives, and Management of Surgical Patients. <i>American Journal of Cardiology</i> , 2007, 100, S18-S25.	0.7	28
144	Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks. <i>Thrombosis and Haemostasis</i> , 2011, 106, 248-252.	1.8	28

#	ARTICLE	IF	CITATIONS
145	Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy?. <i>Circulation</i> , 2018, 138, 2145-2159.	1.6	28
146	The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014, 112, 589-597.	1.8	27
147	Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. <i>Korean Circulation Journal</i> , 2021, 51, 202.	0.7	27
148	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27
149	Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. <i>Coronary Artery Disease</i> , 1998, 9, 451-456.	0.3	26
150	Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 217-220.	1.0	26
151	Assessing the Current Role of Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, I10-I16.	0.7	26
152	Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1040-1051.	0.7	26
153	Ticagrelor for the treatment of arterial thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2251-2259.	0.9	24
154	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€”Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018, 198, 152-159.	1.2	24
155	Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. <i>Journal of Invasive Cardiology</i> , 2002, 14, 584-9.	0.4	24
156	Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 15-22.	1.0	23
157	Pharmacology of Antiplatelet Agents. <i>Current Atherosclerosis Reports</i> , 2013, 15, 371.	2.0	23
158	What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?. <i>Lancet, The</i> , 2013, 382, 633-643.	6.3	22
159	Thrombin-induced platelet-fibrin clot strength: Relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. <i>Thrombosis and Haemostasis</i> , 2014, 111, 713-724.	1.8	22
160	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. <i>American Heart Journal</i> , 2014, 168, 76-87.e1.	1.2	22
161	A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 16-30.	1.0	22
162	Platelet Reactivity and Coagulation Markers in Patients with COVID-19. <i>Advances in Therapy</i> , 2021, 38, 3911-3923.	1.3	22

#	ARTICLE	IF	CITATIONS
163	Prasugrel. Expert Opinion on Investigational Drugs, 2006, 15, 1627-1633.	1.9	21
164	Assessment of oral antithrombotic therapy by platelet function testing. Nature Reviews Cardiology, 2011, 8, 572-579.	6.1	21
165	What is the best measure of thrombotic risksâ€”pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?. Catheterization and Cardiovascular Interventions, 2005, 66, 597-597.	0.7	20
166	Clopidogrel Resistance: Implications for Coronary Stenting. Current Pharmaceutical Design, 2006, 12, 1261-1269.	0.9	20
167	Platelet reactivity and thrombogenicity in postmenopausal women. Menopause, 2013, 20, 57-63.	0.8	20
168	Influence of Race and Sex on Thrombogenicity in a Large Cohort of Coronary Artery Disease Patients. Journal of the American Heart Association, 2014, 3, e001167.	1.6	20
169	Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary noâ€™reflow during primary PCI: The RESTORE observational study. Catheterization and Cardiovascular Interventions, 2021, 97, 602-611.	0.7	20
170	The platelet-related effects of tenecteplase versus alteplase versus reteplase. Blood Coagulation and Fibrinolysis, 2005, 16, 1-7.	0.5	19
171	Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2005, 19, 11-18.	0.6	19
172	Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study. Thrombosis and Haemostasis, 2013, 109, 347-355.	1.8	19
173	Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy. American Journal of Cardiology, 2015, 115, 1204-1211.	0.7	19
174	Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. Thrombosis and Haemostasis, 2021, 121, 1376-1386.	1.8	19
175	Relationship between age and platelet activation in patients with stable and unstable angina. Archives of Gerontology and Geriatrics, 2009, 48, 155-159.	1.4	18
176	Vorapaxar: a novel protease-activated receptor-1 inhibitor. Expert Opinion on Investigational Drugs, 2011, 20, 1445-1453.	1.9	18
177	Toward a therapeutic window for antiplatelet therapy in the elderly. European Heart Journal, 2012, 33, 1187-1189.	1.0	18
178	Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Review of Cardiovascular Therapy, 2013, 11, 447-462.	0.6	18
179	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2990-3003.	1.1	18
180	Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thrombosis and Haemostasis, 2014, 112, 943-950.	1.8	17

#	ARTICLE	IF	CITATIONS
181	Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2016, 118, 1941-1947.	0.7	17
182	Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. <i>Future Cardiology</i> , 2016, 12, 45-58.	0.5	17
183	Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgeryâ€”The BIANCA Observational Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 864-872.	1.8	17
184	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. <i>EClinicalMedicine</i> , 2020, 29-30, 100647.	3.2	17
185	First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab274.	0.4	17
186	Relation of soluble and platelet p-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy. <i>American Journal of Cardiology</i> , 2001, 87, 774-777.	0.7	16
187	Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y ₁₂ receptor inhibitors and high on-treatment platelet reactivity. <i>Platelets</i> , 2013, 24, 166-169.	1.1	16
188	Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2016, 113, 40-45.	1.0	16
189	Pharmacokineticâ€”pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 413-421.	1.1	16
190	Letter by Gurbel et al Regarding Article, â€œCytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placementâ€”. <i>Circulation</i> , 2010, 122, e478; author reply e479.	1.6	15
191	Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 911-922.	1.8	15
192	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 653-665.	0.9	15
193	Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. <i>American Heart Journal</i> , 2000, 139, 0320-0328.	1.2	15
194	High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	14
195	Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2016, 115, 979-992.	1.8	14
196	GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. <i>Lancet, The</i> , 2017, 389, 1773-1775.	6.3	14
197	Exploration of PCSK9 as a Cardiovascular Risk Factor. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1463-1466.	1.2	14
198	Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1277-1286.	1.1	14

#	ARTICLE	IF	CITATIONS
199	â€œBlueprintingâ€•thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 192-199.	1.0	14
200	Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 373-381.	1.0	14
201	Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. <i>Scientific Reports</i> , 2020, 10, 6169.	1.6	14
202	Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 454-465.	1.0	14
203	The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. <i>Thrombosis Research</i> , 2003, 112, 9-12.	0.8	13
204	Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. <i>American Heart Journal</i> , 2013, 166, 95-103.	1.2	13
205	Vorapaxar in the secondary prevention of atherothrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1293-1305.	0.6	13
206	Thrombinâ€•Induced Plateletâ€•Fibrin Clot Strength Identified by Thrombelastography. <i>Journal of Interventional Cardiology</i> , 2016, 29, 168-178.	0.5	13
207	Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with monoâ€•and dualâ€•antiplatelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 23-35.	1.9	13
208	Bedside thromboelastography to rapidly assessâ€•the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 902-904.	1.0	13
209	Adhesion molecules, platelet activation, and cardiovascular risk. <i>American Heart Journal</i> , 2002, 143, 196-198.	1.2	12
210	Platelet activation after stenting with heparin-coated versus noncoated stents. <i>American Heart Journal</i> , 2003, 146, 691.	1.2	12
211	Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009, 11, 22-32.	0.4	12
212	Thienopyridine efficacy and cigarette smoking status. <i>American Heart Journal</i> , 2013, 165, 693-703.	1.2	12
213	Unravelling the Smokersâ€• Paradox: Cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1187-1190.	1.8	12
214	Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCErated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by) Tj ETQq0080 rgBT 10 Overlock 1		
215	<i>Journal of Cardiology</i> , 2015, 190, 370-375.		
215	P2Y12receptor inhibitors for secondary prevention of ischemic stroke. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1149-1165.	0.9	12
216	TEGâ€•6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care. <i>Platelets</i> , 2020, 31, 932-938.	1.1	12

#	ARTICLE	IF	CITATIONS
217	The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 969-981.	1.0	12
218	Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. <i>Anesthesiology</i> , 2020, 133, 1263-1276.	1.3	12
219	Ion channel inhibition against COVID-19: A novel target for clinical investigation. <i>Cardiology Journal</i> , 2020, 27, 421-424.	0.5	12
220	Regional and systemic platelet function is altered by myocardial ischemia-reperfusion. <i>Journal of Thrombosis and Thrombolysis</i> , 1995, 1, 187-194.	1.0	11
221	Short Communication A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened reactivity. <i>Platelets</i> , 2003, 14, 481-483.	1.1	11
222	Delivery of Glycoprotein IIb/IIIa Inhibitor Therapy for Percutaneous Coronary Intervention. <i>Circulation</i> , 2010, 121, 739-741.	1.6	11
223	Cigarette Smoking and Clopidogrel Interaction. <i>Current Cardiology Reports</i> , 2013, 15, 361.	1.3	11
224	Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. <i>Thrombosis and Haemostasis</i> , 2014, 112, 323-331.	1.8	11
225	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 469-476.	1.0	11
226	Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1131-1140.	1.8	11
227	First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition. <i>Circulation</i> , 2020, 142, 1305-1307.	1.6	11
228	Can an Old Ally Defeat a New Enemy?. <i>Circulation</i> , 2020, 142, 315-317.	1.6	11
229	Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 544-549.	0.5	11
230	Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 957-970.	1.5	11
231	Pharmacodynamic Evaluation of Clopidogrel Plus PA32540: The Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) Study. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 860-866.	2.3	10
232	Tratamiento antiagregante plaquetario personalizado. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 480-487.	0.6	10
233	Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel: The Role of VerifyNow. <i>Canadian Journal of Cardiology</i> , 2016, 32, 724-725.	0.8	10
234	Selection of P2Y ₁₂ Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 460-470.	1.6	10

#	ARTICLE	IF	CITATIONS
235	Meta-Analysis of the Usefulness of Therapeutic Hypothermia After Cardiac Arrest. <i>American Journal of Cardiology</i> , 2020, 133, 48-53.	0.7	10
236	Vorapaxar in the treatment of cardiovascular diseases. <i>Future Cardiology</i> , 2020, 16, 373-384.	0.5	10
237	Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a caseâ€“control study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 484-498.	1.0	10
238	Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 449-456.	1.8	10
239	Platelet Reactivity in Patients With Acuteâ€“Coronary Syndromes Awaiting Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1277-1286.	1.2	10
240	International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 992-998.	1.0	10
241	Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2021, 6, 749-761.	1.9	10
242	Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 363.	1.0	10
243	The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7 Suppl 4, S20-8.	0.5	10
244	Response variability and the role of platelet function testing. <i>Journal of Invasive Cardiology</i> , 2009, 21, 172-8.	0.4	10
245	Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. <i>Clinical Cardiology</i> , 2008, 31, I2-I9.	0.7	9
246	The Rationale for and Comparisons of Different Antiplatelet Treatments in Acute Coronary Syndrome. <i>Journal of Interventional Cardiology</i> , 2008, 21, S10-7.	0.5	9
247	Acceptance of High Platelet Reactivity as a Risk Factor. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1008-1010.	1.1	9
248	Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 233.	1.0	9
249	Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 12-20.	1.8	9
250	Importance of potent P2Y12receptor blockade in acute myocardial infarction: focus on prasugrel. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1771-1796.	0.9	9
251	The Clopidogrel-Statin Interaction. <i>Circulation Journal</i> , 2014, 78, 592-594.	0.7	9
252	Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 173-176.	1.0	9

#	ARTICLE	IF	CITATIONS
253	Platelet Function Testing Before CABG is Recommended in the Guidelines: But Do We Have Enough Evidence?. <i>Journal of Interventional Cardiology</i> , 2015, 28, 233-235.	0.5	8
254	Central aortic pulse pressure, thrombogenicity and cardiovascular risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 223-233.	1.0	8
255	Investigational drugs in phase II clinical trials for acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 33-47.	1.9	8
256	Relation of High LipoproteinÂ(a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. <i>Advances in Therapy</i> , 2020, 37, 4568-4584.	1.3	8
257	Pretreatment with an Inhibitor of Mac-1 Alters Regional and Systemic Platelet Function during Ischemia-Reperfusion in Swine. <i>Pharmacology</i> , 1996, 53, 79-86.	0.9	7
258	Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 213-219.	1.0	7
259	Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. <i>Clinical Cardiology</i> , 2008, 31, 121-127.	0.7	7
260	Immunity to thrombotic events is achievable if we stop the guessing game: Is this the major hidden message from GRAVITAS?. <i>Thrombosis and Haemostasis</i> , 2011, 106, 263-264.	1.8	7
261	The Dogged Search for Cryptic Effects of Ticagrelor. <i>Circulation</i> , 2016, 134, 1720-1723.	1.6	7
262	The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 109-121.	1.0	7
263	Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 18-26.	1.0	7
264	Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 243-248.	1.6	7
265	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020, 27, 661-676.	0.5	7
266	Abstract 5603: Oral Dosing of PRT060128, a Novel Direct-acting, Reversible P2Y ₁₂ Antagonist Overcomes High Platelet Reactivity in Patients Non-responsive to Clopidogrel Therapy. <i>Circulation</i> , 2008, 118, .	1.6	7
267	Prasugrel, a third generation thienopyridine and potent platelet inhibitor. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 324-36.	2.3	7
268	The Potential of Monoclonal Antibodies to Reduce Reperfusion Injury in Myocardial Infarction. <i>BioDrugs</i> , 2001, 15, 395-404.	2.2	6
269	Platelet Function and Fibrinolytic Agents: Two Sides of a Coin?. <i>Cardiology</i> , 2001, 95, 55-60.	0.6	6
270	Cutaneous Clopidogrel Hypersensitivity. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1455-1456.	1.2	6

#	ARTICLE	IF	CITATIONS
271	Further Ex Vivo Evidence Supporting Higher Aspirin Dosing in Patients With Coronary Artery Disease and Diabetes. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 118-120.	1.4	6
272	High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype: Figure 1. <i>Heart</i> , 2012, 98, 343.1-343.	1.2	6
273	Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. <i>American Heart Journal</i> , 2013, 165, 176-182.	1.2	6
274	Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring. , 2013, , 45-112.		6
275	Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1259-1267.	0.6	6
276	Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1198-1208.	1.8	6
277	State of the art: Oral antiplatelet therapy. <i>JRSM Cardiovascular Disease</i> , 2016, 5, 204800401665251.	0.4	6
278	Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 123-131.	0.9	6
279	Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 260-264.	1.0	6
280	Deficiency of MMP1a (Matrix Metalloprotease 1a) Collagenase Suppresses Development of Atherosclerosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e265-e279.	1.1	6
281	The role of viscoelastic testing in assessing peri-interventional platelet function and coagulation. <i>Platelets</i> , 2022, 33, 520-530.	1.1	6
282	Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography. <i>TH Open</i> , 2021, 05, e570-e576.	0.7	6
283	Point-of-Care Platelet Function Analysis. <i>Journal of the American College of Cardiology</i> , 2009, 53, 857-859.	1.2	5
284	Cilostazol to Overcome High On-Treatment Platelet Reactivity in Korean Patients Treated With Clopidogrel and Calcium-Channel Blocker. <i>Circulation Journal</i> , 2011, 75, 2534-2536.	0.7	5
285	Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 645-653.	1.3	5
286	The enigmatic search for optimal DAPT duration. <i>European Heart Journal</i> , 2014, 35, 951-954.	1.0	5
287	Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study. <i>International Journal of Cardiology</i> , 2014, 174, 129-132.	0.8	5
288	Association of weight gain with coronary artery disease, inflammation and thrombogenicity. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 394-403.	1.0	5

#	ARTICLE	IF	CITATIONS
289	Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma. <i>European Heart Journal</i> , 2016, 37, 1143-1144.	1.0	5
290	HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm. <i>European Heart Journal</i> , 2017, 38, ehw630.	1.0	5
291	Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. <i>Atherosclerosis</i> , 2018, 268, 55-62.	0.4	5
292	Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opinion on Pharmacotherapy, 2018, 19, 1389-1398.	0.9	5
293	Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 2720.	1.0	5
294	Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention. <i>JACC Asia</i> , 2022, 2, 323-337.	0.5	5
295	Antiplatelet effects of aspirin with phytosterols: Comparison with non-enteric coated aspirin alone. <i>Thrombosis Research</i> , 2010, 126, 384-385.	0.8	4
296	Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1547-1556.	0.6	4
297	PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. <i>Future Cardiology</i> , 2013, 9, 785-797.	0.5	4
298	Pharmacodynamic Effects of Cilostazol Versus Clopidogrel in Stented Patients under Proton Pump Inhibitor Co-administration: The ACCEL-PARAZOL Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 1121-1139.	0.9	4
299	What have we learned from the ANTARCTIC trial?. <i>Nature Reviews Cardiology</i> , 2016, 13, 639-640.	6.1	4
300	Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	4
301	Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. <i>Platelets</i> , 2017, 28, 187-193.	1.1	4
302	Bioprosthetic Valve Thrombosis: Insights from Transcatheter and Surgical Implants. <i>Structural Heart</i> , 2020, 4, 382-388.	0.2	4
303	Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. <i>Future Cardiology</i> , 2020, 16, 69-75.	0.5	4
304	A Canine Model of Acute Coronary Artery Thrombosis for the Evaluation of Reperfusion Strategies. <i>Cardiology</i> , 1994, 84, 1-8.	0.6	3
305	THE INFLUENCE OF CYTOCHROME P450 2C19*2 AND*17 GENOTYPE, DIPLTYPE AND METABOLIZER STATUS ON PLATELET REACTIVITY IN PATIENTS ON MAINTENANCE CLOPIDOGREL THERAPY. <i>Journal of the American College of Cardiology</i> , 2010, 55, A130.E1220.	1.2	3
306	Platelet Function Measurement in Elective Percutaneous Coronary Intervention Patients. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 290-292.	1.1	3

#	ARTICLE	IF	CITATIONS
307	Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. <i>Interventional Cardiology Clinics</i> , 2012, 1, 223-230.	0.2	3
308	Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013, 168, 427-435.	0.8	3
309	Novel Antiplatelet Agents in Cardiovascular Medicine. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 383.	0.4	3
310	Platelet Activation and Pneumonia. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1492-1493.	1.2	3
311	Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. <i>Heart</i> , 2016, 102, 882-892.	1.2	3
312	Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1361-1370.	0.6	3
313	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 779-791.	0.6	3
314	Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	3
315	The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy. <i>European Heart Journal</i> , 2019, 40, 2441-2443.	1.0	3
316	Platelet Activation and Aggregation in Patients with Advanced Adenocarcinoma Undergoing Chemotherapy: Correlation with a Validated Venous Thromboembolism Risk Score. <i>Blood</i> , 2015, 126, 3445-3445.	0.6	3
317	Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can Thrombin Pathway Be a New Target for Therapy?. <i>Korean Circulation Journal</i> , 2020, 50, 817.	0.7	3
318	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , 2021, , .	0.5	3
319	Clinical applications of antiplatelet therapy. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7, 130-46; quiz 148-9.	0.5	3
320	Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, 128-135.	0.7	2
321	Treatment Strategies in Non-ST-Elevation Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention: An Evidence-Based Review of Clinical Trial Results and Treatment Guidelines: Report on a Roundtable Discussion. <i>Journal of Interventional Cardiology</i> , 2008, 21, 283-299.	0.5	2
322	The Worry About Clopidogrel Nonresponsiveness. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1102-1104.	1.1	2
323	Do East Asians have different hypercoagulable states compared with Western population?. <i>American Heart Journal</i> , 2011, 162, e19-e20.	1.2	2
324	The next 10 years in personalized medicine in cardiology. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 933-935.	0.6	2

#	ARTICLE	IF	CITATIONS
325	Monitoring of Antiplatelet Therapy. , 2013, , 603-633.		2
326	Inhibited and Uninhibited Platelet Deposition Within a Thrombus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2081-2082.	1.1	2
327	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Nonâ€œST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). American Journal of Cardiology, 2018, 122, 1322-1329.	0.7	2
328	Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. Thrombosis and Haemostasis, 2019, 119, 264-273.	1.8	2
329	An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 40-50.	1.0	2
330	Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists. Journal of Thrombosis and Thrombolysis, 2021, 52, 272-280.	1.0	2
331	High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases. Arquivos Brasileiros De Cardiologia, 2019, 113, 357-363.	0.3	2
332	Further evidence for the use of aspirin in COVID-19. International Journal of Cardiology, 2021, 346, 107-108.	0.8	2
333	Antiplatelet treatment of cardiovascular disease: a translational research perspective. , 2008, 118, 289-97.		2
334	Correction of a saphenous vein graft to coronary vein anastomosis by selective retrograde coil-induced occlusion to arterialize the native vein. Catheterization and Cardiovascular Interventions, 2002, 57, 541-544.	0.7	1
335	Response to the Letter Regarding Article, â€œEvaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Studyâ€• Circulation, 2008, 117, .	1.6	1
336	Personalized antiplatelet therapy: state of the art. JRSM Cardiovascular Disease, 2012, 1, 1-10.	0.4	1
337	TCT-54 The Influence of Smoking Status On The Pharmacodynamics of Prasugrel and Clopidogrel:The PARADOX Study. Journal of the American College of Cardiology, 2012, 60, B17.	1.2	1
338	The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. Interventional Cardiology Clinics, 2013, 2, 607-614.	0.2	1
339	Triple Antithrombotic Therapy With Prasugrel in the Stented Patient. Journal of the American College of Cardiology, 2013, 61, 2067-2069.	1.2	1
340	Letter by Gurbel et al Regarding Article, â€œAdministration of a Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch From Ongoing Clopidogrel Treatment to Ticagrelor in Patients With Acute Coronary Syndromeâ€• Circulation: Cardiovascular Interventions, 2014, 7, 273-273.	1.4	1
341	Personalized Antiplatelet Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 480-487.	0.4	1
342	PRASFIT-ACS: Important Evidence Against a â€œOne-Guideline-Fits-All-Racesâ€• Approach to Antiplatelet Therapy. Circulation Journal, 2014, 78, 2563.	0.7	1

#	ARTICLE	IF	CITATIONS
343	Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy?. <i>Platelets</i> , 2015, 26, 608-609.	1.1	1
344	Secondary prevention of ischaemic stroke: more evidence to block two pathways affecting platelet activation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 275-278.	1.8	1
345	Phosphodiesterase Inhibitors. , 2019, , 979-989.		1
346	POINT-OF-CARE CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN CARDIAC CATHETERIZATION LABORATORY AND CLINICAL OUTCOMES AFTER PCI. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1329.	1.2	1
347	Pharmacogenetic considerations in antiplatelet therapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 235-238.	0.4	1
348	Assessing platelet reactivity after drug eluting stent implantation: state of the art. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 17-24.	0.6	1
349	Abstract 16676: Heightened Platelet Function: An Unrecognized Component of the Covid Hypercoagulability State. <i>Circulation</i> , 2020, 142, .	1.6	1
350	Antiplatelet Resistanceâ€”Fact or Myth?. <i>The American Heart Hospital Journal</i> , 2009, 7, 50.	0.2	1
351	Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing. <i>Korean Circulation Journal</i> , 2019, 49, 1062.	0.7	1
352	Abstract 3472: The Prediction of Ischemic Events After Percutaneous Coronary Intervention by Platelet Reactivity to Adenosine Diphosphate: First Evidence for an Oral Antiplatelet Therapeutic Target Determined by an <i>Ex Vivo</i> Test of Platelet Function.. <i>Circulation</i> , 2007, 116, .	1.6	1
353	Abstract 4017: Reduced Anti-Platelet Response to Clopidogrel in Diabetic Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2008, 118, .	1.6	1
354	In vitro evidence for the role of cytokine storm in the generation of stent thrombosis in COVID -19 patients. <i>Cardiovascular Revascularization Medicine</i> , 2021, 35, 139-139.	0.3	1
355	Diagnostics for Aspirin Resistance. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 55-56.	1.6	0
356	Thienopyridine Response Variability and Resistance. , 0, , 77-93.		0
357	We Need Further Studies for the Development of â€œOptimized Antiplatelet Therapyâ€”Based on Ethnicity. <i>Journal of the American College of Cardiology</i> , 2011, 58, 198.	1.2	0
358	The Role of Platelet Function Testing and Genotyping in the Stented Patient Treated With Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2701-2702.	1.2	0
359	Role of ticagrelor in the treatment of coronary artery disease. <i>Clinical Investigation</i> , 2011, 1, 429-437.	0.0	0
360	Response to Letter Regarding Article, â€œPlatelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery: The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Studyâ€” <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, .	1.4	0

#	ARTICLE	IF	CITATIONS
361	Ticagrelor in the treatment of coronary artery disease patients. <i>Clinical Practice (London, England)</i> , 2012, 9, 373-390.	0.1	0
362	Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y ₁₂ receptor inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1011-1022.	0.6	0
363	P2Y ₁₂ Receptor Blockade and Myocardial Perfusion. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 684-686.	1.1	0
364	A Bigger Look Into the "Therapeutic Window" of Platelet Reactivity to Adenosine Diphosphate. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1988-1989.	1.1	0
365	To stop or continue aspirin before aortocoronary bypass operations" do we have enough evidence to adequately guide us?. <i>Journal of Thoracic Disease</i> , 2016, 8, E578-E580.	0.6	0
366	Cigarette Smoking, Clopidogrel Responsiveness, and Hemoglobin Level. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2364.	1.1	0
367	Thromboembolism after WATCHMAN TM in a clopidogrel non-responder: A case for concern?. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 200-202.	0.7	0
368	The potential of genotype-guided antiplatelet therapy: promises and challenges. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 371-377.	0.4	0
369	Antithrombotic treatment strategies after PCI. <i>Lancet, The</i> , 2020, 395, 866-867.	6.3	0
370	Is a personalized pharmacotherapeutic approach closed for acute coronary syndrome?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 527-529.	0.9	0
371	Resistance to antiplatelet drugs. , 2007, , 139-154.		0
372	Markers of Platelet Function. <i>Fundamental and Clinical Cardiology</i> , 2009, , 409-428.	0.0	0
373	Antiplatelet Therapy. , 2011, , 201-221.		0
374	Percutaneous Coronary Intervention: Adjunctive Pharmacology. , 2018, , 161-180.		0
375	Antiplatelet Agent Choice and Platelet Function Testing in CKD. , 2020, , 103-118.		0
376	Is clopidogrel as the P2Y ₁₂ inhibitor a wise choice for long-term monotherapy in patients undergoing stenting?. <i>EuroIntervention</i> , 2021, 17, e865-e866.	1.4	0
377	Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	0